breaking news

PRA to buy CRI Lifetree

By Gareth Macdonald contact

- Last updated on GMT

PRA to buy CRI Lifetree
PRA to buy CRI Lifetree
US CRO PRA International has announced plans to buy privately-owned early phase trial specialist CRI Lifetree.

The proposed deal - financial terms of which were not disclosed - will add CRI's three clinical pharmacology centers housing nearly 200 beds to PRA's network.

PRA CEO Colin Shannon said: “CRI Lifetree highly complements PRA’s services and capabilities.Together we are building a leading early Phase CNS platform capable of providing clients with a comprehensive set of specialized clinical services​.”

This was echoed by Willem Jan Drijfhout, executive vice president and managing director of early development services, who said the deal will position PRA at the forefront of  Phase I clinical trials.

News of the acqusition comes a little under six months after PRA was bought by private equity firm Kohlberg Kravis Roberts (KKR) although, judging by what Shannon told Outsourcing-pharma.com at the time, the CRI deal is unlikely to have been driven my KKR.

Speaking in June Shannon told us, “I run the company​,” adding that they will offer some strategic influence, but “ultimately I make the choices​,” as it was with the company’s previous private equity owner Genstar​.

They’re there to help us and not interfere​,” Shannon added, noting KKR’s $78B in assets will help PRA find ways to build and improve.

The CRI acquisition also comes just four months PRA bought and merged with RPS.

CRI Lifetree formed in 2011 when CRI Worldwide has acquired Lifetree Clinical Research to double its Phase I capacity and expand therapeutic expertise.

That deal combined Lifetree's 60 bed, 35,000 sq ft clinical trial facility in Salt Lake City, Utah, US with CRI's Phase I sites in New Jersey and Pennsylvania.

Human abuse liability, analgesia pain model development, sleep medicine and addiction are areas of expertise at CRI Lifetree.

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 15-Aug-2022 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Related suppliers

Follow us

Products

View more

Webinars